HEMISPHERX BIOPHARMA INC Contracts & Agreements

Common Stock Certificate (Filed With SEC on November 14, 2024)

September 19, 2024 Lease extension for Riverton office (Filed With SEC on November 14, 2024)

Placement Agency Agreement, dated September 30, 2024, by and between the Company and Maxim Group LLC (Filed With SEC on October 1, 2024)

Form of Class C Warrants to Purchase Common Stock (Filed With SEC on October 1, 2024)

Form of Class D Warrants to Purchase Common Stock (Filed With SEC on October 1, 2024)

Form of Securities Purchase Agreement, dated as of September 30, 2024, by and among the Company and the investor parties thereto (Filed With SEC on October 1, 2024)

September 11, 2024 amendment to the employment agreement of Thomas K. Equels (Filed With SEC on September 12, 2024)

September 11, 2024 amendment to the employment agreement of Peter W. Rodino, III (Filed With SEC on September 12, 2024)

August 12, 2024 Amendment to Employment Agreement for Thomas K Equels (Filed With SEC on August 14, 2024)

August 12, 2024 Amendment to Employment Agreement for Peter W Rodino III (Filed With SEC on August 14, 2024)

October 4, 2023 Lease extension for Riverton office (Filed With SEC on April 19, 2024)

March 15, 2024 Addendum 1 to Lease for Ocala office (Filed With SEC on April 19, 2024)

Description of Common Stock (Filed With SEC on April 1, 2024)

Atlas Equity Purchase Agreement (Filed With SEC on April 1, 2024)

Atlas Registration Rights Agreement (Filed With SEC on April 1, 2024)

Note Purchase Agreement dated February 16, 2024, between AIM ImmunoTech Inc. and Streeterville Capital, LLC (Filed With SEC on February 20, 2024)

Promissory Note dated February 16, 2024, between AIM ImmunoTech Inc. and Streeterville Capital, LLC (Filed With SEC on February 20, 2024)

Amended and Restated Material Transfer and Research Agreement with Roswell Park Cancer Institute Corporation (Filed With SEC on September 29, 2023)

Material Transfer and Research Agreement, dated as of May 22, 2023, by and between AIM ImmunoTech Inc. and Japanese National Institute of Infectious Disease. (portions of this... (Filed With SEC on May 30, 2023)

Equity Distribution Agreement, dated as of April 19, 2023, by and between AIM Immunotech Inc. and Maxim Group LLC (Filed With SEC on April 19, 2023)

Unrestricted Grant Agreement with Erasmus University Medical Center (Filed With SEC on April 7, 2023)

Independent Contractor Services Agreement with Casper H. J. van Eijck (Filed With SEC on April 7, 2023)

Description of Common Stock (Filed With SEC on March 31, 2023)

December 5, 2022 Master Service Agreement between Sterling Pharma Solutions Limited and AIM ImmunoTech Inc (Filed With SEC on March 31, 2023)

January 13, 2023 Study Support Agreement with Erasmus University Medical Center Rotterdam (portions of this agreement have been redacted in compliance with Regulation S-K Item... (Filed With SEC on March 31, 2023)

January 13, 2023 Co-ordination Agreement with Erasmus University Medical Center Rotterdam and AstraZeneca BV (portions of this agreement have been redacted in compliance with... (Filed With SEC on March 31, 2023)

March 1, 2023 Extension Agreement with Foresite Advisors LLC (Filed With SEC on March 31, 2023)

Amendment to the November 14, 2017 Second Amended and Restated Rights Agreement as of November 9, 2022, by and between AIM ImmunoTech Inc. (f/k/a Hemispherx Biopharma, Inc.) and... (Filed With SEC on November 14, 2022)

October 5, 2022 Lease extension for Riverton office (Filed With SEC on November 14, 2022)

October 11, 2022 Material Transfer and Research Agreement with University of Pittsburgh (portions of this agreement have been redacted in compliance with Regulation S-K Item... (Filed With SEC on November 14, 2022)

October 21, 2022 Material Transfer and Research Agreement with University of Pittsburgh (portions of this agreement have been redacted in compliance with Regulation S-K Item... (Filed With SEC on November 14, 2022)

October 21, 2022 Fourth Amendment to Agreement of Sale and Purchase with Acellories, Inc (Filed With SEC on November 14, 2022)

June 27, 2022 First Amendment to Agreement of Sale and Purchase with Acellories, Inc (Filed With SEC on August 15, 2022)

August 2, 2022 Second Amendment to Agreement of Sale and Purchase with Acellories, Inc (Filed With SEC on August 15, 2022)

August 10, 2022 Termination agreement with Shenzhen Smoore Technology Limited (Filed With SEC on August 15, 2022)

June 16, 2022 Lease Agreement with NJEDA (Filed With SEC on June 21, 2022)

June 13, 2022 Amarex Work Order (portions of this Agreement have been redacted in compliance with Regulation S-K Item 601(b)(10)) (Filed With SEC on June 17, 2022)

April 7, 2022 Amarex Work Order (portions of this Agreement have been redacted in compliance with Regulation S-K Item 601(b)(10)) (Filed With SEC on April 12, 2022)

Description of Common Stock (Filed With SEC on March 31, 2022)

March 1, 2022 Consulting Agreement with Foresite Advisors, LLC pursuant to which Robert Dickey IV will serve as the Companys Chief Financial Officer (Portions of this agreement... (Filed With SEC on March 31, 2022)

March 24, 2022 Consulting Agreement with Ellen Lintal (Portions of this agreement have been redacted in compliance with Regulation S-K Item 601(b)(10)) (Filed With SEC on March 31, 2022)

March 1, 2022 Amendment to Clinical Trial Agreement with hVIVO Services Ltd dated September 27, 2021 (Filed With SEC on March 31, 2022)

March 3, 2022 Agreement of Sale and Purchase with Acellories, Inc for sale of 783 Jersey Avenue, New Brunswick, NJ building (Filed With SEC on March 31, 2022)

March 8, 2022 Change order to Master Service Agreement with Pharmaceutics International Inc. as a Fill & Finish provider for Ampligen (Filed With SEC on March 31, 2022)

September 27, 2021 Clinical Trial Agreement with hVIVO Services Limited (Portions of this Agreement have been redacted in compliance with Regulation S-K Item 601(b)(10)) (Filed With SEC on November 15, 2021)

July 8, 2021 Reservation and Start-Up Agreement with hVIVO Services Limited (Portions of this Agreement have been redacted in compliance with Regulation S-K Item 601(b)(10)) (Filed With SEC on August 16, 2021)

May 21, 2021 extension of April 1, 2020 Material Transfer and Research Agreement with Shenzhen Smoore Technology Limited (Filed With SEC on August 16, 2021)

April 1, 2021 extension of April 1, 2020 Material Transfer and Research Agreement with Shenzhen Smoore Technology Limited (Filed With SEC on August 16, 2021)

April 19, 2021 Purchase and Sale Agreement with Phoenix Equipment Corporation, Branford Auctions, LLC and Perry Videx LLC (Filed With SEC on May 17, 2021)

Material Transfer and Research agreement with Roswell Park Comprehensive Cancer Center executed on April 14, 2021 (Portions of this Agreement have been redacted in compliance with... (Filed With SEC on May 17, 2021)

May 1, 2021 extension of April 1, 2020 Material Transfer and Research Agreement with Shenzhen Smoore Technology Limited (Filed With SEC on May 17, 2021)

Material Transfer And Research Agreement with the University of Cagliari Dipartimento di Scienze della Vita e dellAmbiente executed on April 5, 2021 (Portions of this Agreement... (Filed With SEC on May 17, 2021)

May 12, 2021 Amendment to the Renewed Sales, Marketing, Distribution and Supply Agreement with GPPharm. (Portions of this Agreement have been redacted in compliance with... (Filed With SEC on May 17, 2021)

Description of Common Stock (Filed With SEC on March 31, 2021)

December 22, 2020 Master Service Agreement with Pharmaceutics International Inc. as a Fill & Finish provider for Ampligen (Filed With SEC on March 31, 2021)

January 11, 2021 Sponsor Agreement with Centre for Human Drug Research. (Portions of this Agreement have been redacted in compliance with Regulation S-K Item 601(b)(10)) (Filed With SEC on March 31, 2021)

November 29, 2020, Material Transfer and Research Agreement with Leyden Laboratories, B.V. (Portions of this Agreement have been redacted in compliance with Regulation S-K Item... (Filed With SEC on March 31, 2021)

December 30, 2020 Amendment to Project Work Order with Amarex Clinical Research LLC. (Portions of this Agreement have been redacted in compliance with Regulation S-K Item... (Filed With SEC on March 31, 2021)

December 23, 2020 Amendment to Master Service Agreement with Pharmaceutics International Inc. as a Fill & Finish provider for Ampligen (Filed With SEC on March 31, 2021)

March 24, 2021 employment agreement with Peter Rodino (Filed With SEC on March 31, 2021)

March 24, 2021 employment agreement with Ellen Lintal (Filed With SEC on March 31, 2021)

November 10, 2020 employment agreement with Thomas K. Equels (Filed With SEC on November 12, 2020)

June 1, 2020, Material Transfer and Research Agreement with the University of Rochester. (Portions of this Agreement have been redacted in compliance with Regulation S-K Item... (Filed With SEC on August 14, 2020)

June 23, 2020, Specialized Services Agreement with Utah State University. (Portions of this Agreement have been redacted in compliance with Regulation S-K Item 601(b)(10)) (Filed With SEC on August 14, 2020)

July 1, 2020, Material Transfer and Research Agreement with the Japanese National Institute of Infectious Diseases and Shionogi & Co., Ltd. (Portions of this Agreement have been... (Filed With SEC on August 14, 2020)

July 6, 2020, Clinical Trial Agreement with Roswell Park Comprehensive Cancer Center. (Portions of this Agreement have been redacted in compliance with Regulation S-K Item... (Filed With SEC on August 14, 2020)

August 6, 2020, Project Work Order with Amarex Clinical Research LLC. (Portions of this Agreement have been redacted in compliance with Regulation S-K Item 601(b)(10)) (Filed With SEC on August 14, 2020)

April 21, 2020 Mutual Confidentiality Agreement with UMN Pharma Inc., National Institute of Infectious Diseases, and Shionogi & Co., Ltd (Filed With SEC on April 27, 2020)

April 1, 2020 Material Transfer and Research Agreement with Shenzhen Smoore Technology Limited (Filed With SEC on April 6, 2020)

Description of Common Stock (Filed With SEC on March 30, 2020)

Amendment to 2017 Material Transfer and Research Agreement with Roswell Park Cancer Institute (Filed With SEC on March 26, 2020)

December 5, 2019 Note Purchase Agreement between the Company and Atlas Sciences, LLC (Filed With SEC on December 11, 2019)

December 5, 2019 Secured Promissory Note from the Company to Atlas Sciences, LLC (Filed With SEC on December 11, 2019)

December 5, 2019 Security Agreement between the Company and Atlas Sciences, LLC (Filed With SEC on December 11, 2019)

Underwriting Agreement, dated September 25, 2019 between the Company and A.G.P./Alliance Global Partners, LLC (Filed With SEC on September 27, 2019)

Form of Pre-Funded Warrant (Filed With SEC on September 27, 2019)

Form of Warrant (Filed With SEC on September 27, 2019)

Underwriting Agreement (Filed With SEC on September 24, 2019)

Form of Representatives Warrant (Filed With SEC on September 24, 2019)

Form of Pre-Funded Warrant (Filed With SEC on September 6, 2019)

Form of Warrant (Filed With SEC on September 6, 2019)

Salary Reduction and Restricted Stock Award Memo (Filed With SEC on August 26, 2019)

Form of Restricted Stock Award (Filed With SEC on August 26, 2019)

Note Purchase Agreement dated August 5, 2019 with Chicago Ventures Partners, L.P (Filed With SEC on August 14, 2019)

Secured Promissory Note dated August 5, 2019 issued to Chicago Ventures Partners, L.P (Filed With SEC on August 14, 2019)

Security Agreement dated August 5, 2019 with Chicago Ventures Partners, L.P (Filed With SEC on August 14, 2019)

Notice of Termination of Equity Distribution Agreement, dated as of July 23, 2012, by and between Hemispherx Biopharma, Inc. and Maxim Group LLC (Filed With SEC on July 22, 2019)

Equity Distribution Agreement, dated as of July 19, 2019, by and between Hemispherx Biopharma, Inc. and Maxim Group LLC (Filed With SEC on July 22, 2019)

Form of Agreement between the Company and the Warrantholders (Filed With SEC on May 2, 2019)

March 13, 2019 amendment to the September 28, 2018 Secured Convertible Promissory Note from the Company to Iliad Research and Trading, L.P (Filed With SEC on March 15, 2019)

Warrant Agency Agreement with American Stock Transfer & Trust Company, LLC (Filed With SEC on March 8, 2019)

Revised Form of Warrant Certificate for Rights Offering (Filed With SEC on February 27, 2019)

Form of Dealer - Manager Agreement (Filed With SEC on February 6, 2019)

Form of Non-Transferable Subscription Rights Certificate (Filed With SEC on February 6, 2019)

Form of Warrant Agreement (Filed With SEC on February 6, 2019)

Chardan Equity Distribution Agreement Termination letter (Filed With SEC on December 11, 2018)

October 9, 2018, Clinical Trial Agreement with Roswell Park Comprehensive Cancer Center (Filed With SEC on November 14, 2018)

October 8, 2018, Restated First Amendment to Purchase and Sale Agreement (Filed With SEC on November 14, 2018)

October 9, 2018, Restated Bill of Sale for the Restated First Amendment and Sale Agreement (Filed With SEC on November 14, 2018)

September 28, 2018 Securities Purchase Agreement between the Company and Iliad Research and Trading, L.P (Filed With SEC on October 4, 2018)

September 28, 2018 Secured Convertible Promissory Note from the Company to Iliad Research and Trading, L.P (Filed With SEC on October 4, 2018)

September 28, 2018 Security Agreement between the Company and Iliad Research and Trading, L.P (Filed With SEC on October 4, 2018)

August 3, 2018 Amendment to Equity Distribution Agreement between the registrant and Maxim Group LLC (Filed With SEC on August 3, 2018)

Form of Class A Warrant (Filed With SEC on April 20, 2018)

Form of Class B Warrant (Filed With SEC on April 20, 2018)

Form of Securities Purchase Agreement (Filed With SEC on April 20, 2018)

Form of Warrant issued to Purchaser of facility (Filed With SEC on March 30, 2018)

December 13, 2016 Amendment No. 1 to Amended and Restated Early Access Agreement with Impatients N.V (Filed With SEC on March 30, 2018)

June 28, 2017 Amendment No. 2 to Amended and Restated Early Access Agreement with Impatients N.V (Filed With SEC on March 30, 2018)

February 14, 2018 Amendment No. 3 to Amended and Restated Early Access Agreement with Impatients N.V (Filed With SEC on March 30, 2018)

March 26, 2018 Amendment No. 4 to Amended and Restated Early Access Agreement with Impatients N.V (Filed With SEC on March 30, 2018)

September 11, 2017 Purchase and Sale Agreement- 5 Jules Lane (Filed With SEC on March 30, 2018)

January 8, 2018 Purchase and Sale Agreement- 783 Jersey Lane (Filed With SEC on March 30, 2018)

Lease Agreement for 783 Jersey Lane (Filed With SEC on March 30, 2018)

Engagement Letter, dated as of March 21, 2018 by and between Hemispherx Biopharma, Inc. and Ascendiant Capital Markets LLC (Filed With SEC on March 22, 2018)

Form of Securities Purchase Agreement (Filed With SEC on March 22, 2018)

THISDOCUMENT CONSTITUTES PART OF A PROSPECTUS COVERING SECURITIESTHAT HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933. HemispherxBiopharma, Inc. Employee 2017Temporary Stock... (Filed With SEC on August 29, 2017)

SERIESA COMMON STOCK PURCHASE WARRANT hemispherxbiopharma, inc. (Filed With SEC on August 23, 2017)

SERIESB COMMON STOCK PURCHASE WARRANT hemispherxbiopharma, inc. (Filed With SEC on August 23, 2017)

SERIESA COMMON STOCK PURCHASE WARRANT hemispherxbiopharma, inc. (Filed With SEC on June 1, 2017)

SERIESB COMMON STOCK PURCHASE WARRANT hemispherxbiopharma, inc. (Filed With SEC on June 1, 2017)

AnnexA (Filed With SEC on June 1, 2017)

MORTGAGEAND SECURITY AGREEMENT (Filed With SEC on May 15, 2017)

PROMISSORYNOTE (Filed With SEC on May 15, 2017)

AMENDEDAND RESTATED EARLY ACCESS AGREEMENT (Filed With SEC on May 8, 2017)

430 Park Avenue | New York, NewYork 10022 | 212 ###-###-#### Security services provided by H.C. Wainwright& Co., LLC | Member: FINRA/SIPC (Filed With SEC on February 3, 2017)

COMMON STOCK PURCHASE WARRANT hemispherxbiopharma, inc. (Filed With SEC on February 3, 2017)

SECURITIESPURCHASE AGREEMENT (Filed With SEC on February 3, 2017)

AMENDED AND RESTATED EARLY ACCESS AGREEMENT (Filed With SEC on January 17, 2017)

********************* (Filed With SEC on September 1, 2016)

COMMON STOCK PURCHASE WARRANT hemispherxbiopharma, inc. (Filed With SEC on September 1, 2016)

SECURITIESPURCHASE AGREEMENT (Filed With SEC on September 1, 2016)

{***} Fill/Finish of Ampligen® Bulk Drug Proposal Prepared for Hemispherx Biopharma, Inc. June 20, 2016August 12, 2016 (Filed With SEC on August 15, 2016)

Sales,Marketing, Distribution, and Supply Agreement {***} (Filed With SEC on May 16, 2016)

LICENCE AGREEMENT {***} between {***} and HemispherxBiopharma, Inc (Filed With SEC on May 16, 2016)

HemispherxBiopharma, Inc. 2016Senior Executive Deferred Cash Performance Award Plan (amendedand restated on February 29, 2016) (Filed With SEC on March 1, 2016)

HemispherxBiopharma, Inc. 2016Senior Executive Deferred Cash Performance Award Plan (Filed With SEC on February 4, 2016)

Hemispherx Biopharma, Inc. 2016 Voluntary Incentive Stock AwardPlan (Filed With SEC on February 4, 2016)

Agreed and Accepted: /s/William A. Carter Dr. William A.Carter (Filed With SEC on January 14, 2016)

HEMISPHERX BIOPHARMA, INC. COMMON STOCK EQUITY DISTRIBUTION AGREEMENT (Filed With SEC on December 16, 2015)

Waiver Letter (Filed With SEC on November 23, 2015)

EARLY ACCESS AGREEMENT (Filed With SEC on November 16, 2015)

Addendum to the Early Access Agreement (as defined below) (Filed With SEC on November 16, 2015)

EARLY ACCESS AGREEMENT (Filed With SEC on August 12, 2015)

Sales, Marketing, Distribution, and Supply Agreement (Filed With SEC on August 12, 2015)

[remainder of page intentionally left blank] (Filed With SEC on August 5, 2015)

Sales, Marketing, Distribution, and Supply Agreement (Filed With SEC on March 19, 2015)

EMPLOYMENT AGREEMENT (Filed With SEC on July 10, 2014)

ADVISORS AGREEMENT (Filed With SEC on November 8, 2013)

INDEPENDENT CONTRACTOR AGREEMENT (Filed With SEC on August 9, 2013)

Hemispherx Biopharma, Inc. $75,000,000 Equity Distribution Agreement (Filed With SEC on July 23, 2012)

Amendment to Option/Warrant (Filed With SEC on June 8, 2012)

SECOND AMENDED AND RESTATED ADVISER’SAGREEMENT (Filed With SEC on March 14, 2012)

FourthAmendment to Supply Agreement (Filed With SEC on March 14, 2012)

AMENDED AND RESTATED EMPLOYMENT AGREEMENT (Filed With SEC on December 12, 2011)

HEMISPHERX BIOPHARMA, INC. SPECIALTY DISTRIBUTOR PURCHASE AND SERVICE AGREEMENT (Filed With SEC on November 9, 2011)

AGREEMENT Between ARMADA HEALTH CARE, L.L.C. (Filed With SEC on November 9, 2011)

AMENDED EMPLOYMENT AGREEMENT (Filed With SEC on September 23, 2011)

EMPLOYMENT AGREEMENT (Filed With SEC on May 6, 2011)

EMPLOYMENTAGREEMENT (Filed With SEC on December 8, 2010)

Amended andRestated Employment Agreement with Dr. William A. Carter dated July 152010 AMENDEDEMPLOYMENT AGREEMENT (Filed With SEC on August 6, 2010)

Amended andRestated Employment Agreement with Thomas K. Equels dated July 152010 AMENDEDEMPLOYMENT AGREEMENT (Filed With SEC on August 6, 2010)

Amended andRestated Employment Agreement with Robert Dickey IV dated August 3,2010 EXECUTIVEEMPLOYMENT AGREEMENT BETWEEN HEMISPHERX BOIOPHARMA, INC.AND ROBERT DICKEY IV (Filed With SEC on August 6, 2010)

Amended AdvisorsAgreement with The Sage Group, Inc. dated July 15 2010 AMENDEDADVISERS AGREEMENT (Filed With SEC on August 6, 2010)

AMENDEDAND RESTATED EMPLOYMENT AGREEMENT (Filed With SEC on June 15, 2010)

AMENDEDAND RESTATED ENGAGEMENTAGREEMENT (Filed With SEC on June 15, 2010)

EMPLOYMENTAGREEMENT (Filed With SEC on June 15, 2010)

AMENDEDAND RESTATED ENGAGEMENTAGREEMENT (Filed With SEC on June 15, 2010)

EMPLOYMENTAGREEMENT (Filed With SEC on June 15, 2010)

HemispherxBiopharma, Inc. 32,000,000Shares of Common Stock ParValue $0.001 per Share Equity DistributionAgreement (Filed With SEC on May 28, 2010)

EmploymentAgreement with Robert Dickey IV (Filed With SEC on March 12, 2010)

Amendmentto Supply Agreement with Hollister-Stier Laboratories LLC (Filed With SEC on March 12, 2010)

August2009 Material Evaluation Agreement with Biken MaterialEvaluation Agreement (Filed With SEC on March 12, 2010)

COMMONSTOCK PURCHASE WARRANT HEMISPHERXBIOPHARMA, INC. (Filed With SEC on May 19, 2009)

SECURITIESPURCHASE AGREEMENT (Filed With SEC on May 19, 2009)

RODMAN& RENSHAW (Filed With SEC on May 11, 2009)

COMMONSTOCK PURCHASE WARRANT SERIESI HEMISPHERXBIOPHARMA, INC. (Filed With SEC on May 11, 2009)

COMMONSTOCK PURCHASE WARRANT SERIESII HEMISPHERXBIOPHARMA, INC. (Filed With SEC on May 11, 2009)

SECURITIESPURCHASE AGREEMENT (Filed With SEC on May 11, 2009)

FIRST AMENDMENT TO COMMON STOCK PURCHASE AGREEMENT (Filed With SEC on August 11, 2008)

COMMON STOCK PURCHASE AGREEMENT (Filed With SEC on July 8, 2008)

REGISTRATION RIGHTS AGREEMENT (Filed With SEC on July 8, 2008)

Category

Industry

Companies

Contracts

HEMISPHERX BIOPHARMA INC Contracts & Agreements